References relevant to drug promotion: 1960-1989

This page lists all the 1383 references relevant to drug promotion published in 1960-1989 in the Healthy Skepticism library.

Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.


HSL10174
Conlan MF.
Drug industry must hold down Medicaid costs or states will
Drug Topics 1989 Dec 11;133:48

HSL4457
Wade VA, Mansfield PR, McDonald PJ.
Drug companies' evidence to justify advertising.
Lancet 1989 Nov 25;2(8674):1261-3

HSL4494
Wilkes MS, Shuchman M.
Pitching doctors.
N Y Times Mag 1989 Nov 5:88, 90, 126, 128-129

HSL4492
MaLAM letter follow up—Merck Sharp & Dohme. Are MSD’s distributors uncontrollable?
MaLAM Newsletter 1989 Nov

HSL4493
Re: the promotion of uridine triphosphate
1989 Nov

HSL10172
Prescription drugs: ready for prime time?
National Association of Retail Druggists Journal 1989 Nov;111:26-27, 29-30

HSL10173
West CM.
Independent retail pharmacy in a free-market economy
National Association of Retail Druggists Journal 1989 Nov;111:54-57

HSL4490
Cearnal ME.
Journal advertising works
Medical Marketing & Media 1989 Oct 20;24(12):4,6-10

HSL4486
Re: the promotion of DPT-P vaccine
1989 Oct

HSL4487
MaLAM letter follow up—Wellcome: a welcome withdrawal
MaLAM Newsletter 1989 Oct

HSL4488
Re: the promotion of Franol combination for asthma
1989 Oct

HSL10169
Gervas JJ.
Analysis of the factors inducing the prescription
Farmacia Clinica 1989 Oct;6:588-590, 592-594

HSL10171
Johnson RC.
Seeking sanity in an insane world
California Pharmacist 1989 Oct;37:24, 26-27

HSL10190
Zellmer WA.
Generic drug products.
Am J Hosp Pharm 1989 Oct;46(10):2005

HSL4434
Lexchin J.
Declaration of vested interest.
Lancet 1989 Sep 30;2(8666):806

HSL4408
Engler RL.
The arrhythmia consultation program.
N Engl J Med 1989 Sep 28;321(13):908

HSL4425
Jarman J.
SKF marketing of hepatitis B vaccine.
N Z Med J 1989 Sep 13;102(875):481

HSL4426
Kawachi I.
Fenoterol.
N Z Med J 1989 Sep 13;102(875):478

HSL5826
Borgiel AE, Dunn EV, Lamont CT, MacDonald PJ, Evensen MK, Bass MJ, Spasoff RA, Williams JI.
Recruiting family physicians as participants in research.
Fam Pract 1989 Sep 01;6(3):168-72

HSL10178
Hearing blasts drug manufacturers' emphasis on R&D for me too drugs
American Pharmacy 1989 Sep;29:16

HSL10179
Exposing the inequities: Senate hearing examines prescription drug prices
National Association of Retail Druggists Journal 1989 Sep;111:30-36

HSL10180
Levy RA, Smith DL.
Staying the course: refill reminders can boost sales
Pharmaceutical Executive 1989 Sep;9:74, 76, 78

HSL10181
Koberstein W.
Pitching to new players
Pharmaceutical Executive 1989 Sep;9:12

HSL10182
Schwartz H.
Docs, Danes and dogs: sampler for the industry
Pharmaceutical Executive 1989 Sep;9:18, 20

HSL10183
Bamberger DR.
Industry responds to new law on drug diversion
Pharmaceutical Executive 1989 Sep;9:100, 102, 104, 106

HSL4453
Spiro M.
Genentech, Inc, and symposium sponsorship.
Ann Emerg Med 1989 Aug;18(8):908-9

HSL4483
Children’s vitamin preparations: kidding the kids and their parents
1989 Aug;4(8):109-110

HSL4484
Re: the promotion of serrapeptase
1989 Aug

HSL4485
Greenwood J.
Prescribing and salesmanship
HAI News 1989 Aug(48):1-2, 11

HSL10162
Marsh P.
Prescribing for medical and other headaches
Eastern Pharmacist 1989 Aug;32:63-65

HSL10170
Gagnon JP.
Defining and marketing value-added pharmacy services in a community pharmacy. Part 1
Pharmacy Times 1989 Aug;55:61-62, 66-67

HSL10192
Nonprescription drug industry urges more prescription-to-nonprescription switches
American Journal of Hospital Pharmacy 1989 Aug;46:1512

HSL14039
Rao AR, Monroe KB.
The Effect of Price, Brand Name, and Store Name on Buyers' Perceptions of Product Quality : An Integrative Review.
Journal of Marketing Research 1989 Aug;26(3):351-357
http://www.marketingpower.com/content17866.php

HSL4427
Kiatboonsri P, Richter J.
Dipyrone trials in Thailand.
Lancet 1989 Jul 8;2(8654):107

HSL10185
McLeod DC.
Nonprescription drug approval: therapeutic strategy or marketing decision?
DICP 1989 Jul-Aug;23(7-8):606-9

HSL4452
Solomon SD.
We need ethical guidelines for promotion of prescription drugs to physicians.
N Engl J Med 1989 Jun 22;320(25):1700

HSL4433
Lexchin J.
Advertising drugs to the public.
Lancet 1989 Jun 17;1(8651):1392-3

HSL4451
Scott HV, Ketelbey JW.
Lederfen-F GP trial.
N Z Med J 1989 Jun 14;102(869):299-300

HSL4438
Massam D.
Promotion of medicines.
Lancet 1989 Jun 10;1(8650):1330

HSL4479
MaLAM letter follow-up—Merck Sharp & Dohme. Denial of responsibility
MaLAM Newsletter 1989 Jun

HSL4480
Re: the promotion of tetracycline syrups for children
1989 Jun

HSL4482
Re: the promotion of buflomedil
1989 Jun

HSL10188
Schwartz H.
Prescriptions for profit: muckraking journalism on the PBS frontline
Pharmaceutical Executive 1989 Jun;9:14, 16, 18

HSL10199
Manasse HR Jr.
Medication use in an imperfect world: drug misadventuring as an issue of public policy, Part 2.
Am J Hosp Pharm 1989 Jun;46(6):1141-52

HSL1035
Mansfield PR.
Drug advertising.
Lancet 1989 May 20;1(8647):1137-8

HSL4450
Schwartz TB.
Endorsement of "patient promise" program.
N Engl J Med 1989 May 18;320(20):1354-5

HSL4478
Miller A, Barrett T, Bradburn E.
Pitching to patients
1989 May 8:40-41

HSL4475
IFPMA marketing code in new booklet, available in three languages
Health Horizons 1989 May

HSL4476
Re: the promotion of nicergoline
1989 May

HSL4477
Drug utilization bibliography
1989 May

HSL10176
Schwartz H.
To prescribe or not? Essential and excessive use of pharmaceuticals
Pharmaceutical Executive 1989 May;9:14, 16, 18

HSL10195
McLaughlin SS.
Novel promotional activities, direct-to-consumer advertising subjects of FDA scrutiny
American Journal of Hospital Pharmacy 1989 May;46:870, 875

HSL4423
Holden C.
Research group forswears financial ties to firms whose drugs it tests.
Science 1989 Apr 21;244(4902):282

HSL4473
Humphrey AR.
Treatment of herpes zoster.
N Z Med J 1989 Apr 12;102(865):168

HSL4448
Relman AS.
Economic incentives in clinical investigation.
N Engl J Med 1989 Apr 6;320(14):933-4

HSL4472
Healy B, Campeau L, Gray R, Herd JA, Hoogwerf B, Hunninghake D, Knatterud G, Stewart W, White C.
Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery.
N Engl J Med 1989 Apr 6;320(14):949-51

HSL4471
Moulds RF, Wing LM.
Drug advertising.
Med J Aust 1989 Apr 3;150(7):410-1

HSL4468
This month’s MaLAM letter—Glaxo. Multiple claims, little improvement
MaLAM Newsletter 1989 Apr

HSL4469
Logarta JD.
Generics revisited: an overdose of expectations
Drug Monitor 1989 Apr;4(4):49-54

HSL4470
Vreeland LN.
The selling of Retin-A
Money 1989 Apr:75-80, 84, 87

HSL10189
Weiner JN.
Direct advertising of prescription drugs to consumers
Pennsylvania Pharmacist 1989 Apr;70:140-141

HSL10191
Cramer PK.
States' substitution laws squeeze industry innovators
Pharmaceutical Executive 1989 Apr;9:74, 76, 78, 80

HSL4467
Prescriptions for profit
1989 Mar 28

HSL4406
Dixon RE.
Medical advice by celebrities.
N Engl J Med 1989 Mar 16;320(11):742

HSL4420
Heery PJ.
What influences prescribing--scientific articles or promotional pressure?
Med J Aust 1989 Mar 6;150(5):282,

HSL10197
Rosendahl I.
Warner-Lambert readies Rx/OTC product launches
Drug Topics 1989 Mar 6;133:75

HSL4421
Helwig D.
There's no room for freebies in medical journalism.
CMAJ 1989 Mar 1;140(5):542-3

HSL4456
Thomas J 3rd.
National survey of recent changes in hospital policies on pharmaceutical sales representatives' activities.
Am J Hosp Pharm 1989 Mar;46(3):565-9

HSL10167
What will influence the growth of OTC drug sales?
Pharmacy Times 1989 Mar;55:82, 85-86

HSL10194
Madhaven S.
On-going dilemma of direct to consumer advertising of Rx drugs
W Va Pharm 1989 Mar;13:8-10

HSL10198
Tootelian DH.
Establishing a market niche: meeting the competitive challenge
American Pharmacy 1989 Mar;29:61-69

HSL10208
Rx drugs and the information explosion
American Druggist 1989 Mar;197:50

HSL10214
Louis WJ.
Conflict over drug policy in Australia.
BMJ 1989 Feb 25;298(6672):472-3
Link to source with long URL

HSL4428
Kolbe J, Bai TR.
High-dose inhaled corticosteroids.
N Z Med J 1989 Feb 22;102(862):85

HSL2075
Ferguson RP.
Training the resident to meet the detail men.
JAMA 1989 Feb 17;261(7):992-3

HSL4463
MaLAM letter follow up—Abbott
MaLAM Newsletter 1989 Feb:1

HSL4464
Re: the promotion of ketoconazole
1989 Feb

HSL4465
George RA.
Direct drag promotion does not benefit patients.
J Fla Med Assoc 1989 Feb;76(2):239-40

HSL4466
Sarkar PK, Das SK.
Practitioners' obligation: to the public or the drug industry?
DICP 1989 Feb;23(2):175-6

HSL10193
Benoliel DM.
Original pack dispensing: dream or a reality?
Manufacturing-Chemist 1989 Feb;60:39-40, 42

HSL4127
Birley JL.
Drug advertisements in developing countries.
Lancet 1989 Jan 28;1(8631):220

HSL4407
Duffin JM.
Junk mail.
CMAJ 1989 Jan 15;140(2):112

HSL10213
Guideline labeling texts for progestational drug products for human use
Federal Register 1989 Jan 12;54:1243-1244

HSL4461
Highlights of a survey of Southeast Asian physicians
Drug Monitor 1989 Jan;4(1):8

HSL4462
MaLAM letter follow up—Last gasps for a respiratory stimulant
MaLAM Newsletter 1989 Jan:1

HSL10187
Horvath D.
Problems raised by the necessity of combining preparates of the pharmaceutical industry into magistral prescriptions
Gyogyszereszet 1989 Jan;33:3-4

HSL10201
Worthen DB.
One price for all.
Am Pharm 1989 Jan;NS29(1):8

HSL10202
Work DR.
It's time to take the next step.
Am Pharm 1989 Jan;NS29(1):22-3

HSL2424
Schwartz RK, Soumerai SB, Avorn J.
Physician motivations for nonscientific drug prescribing.
Soc Sci Med 1989;28(6):577-82

HSL2467
Grice HP.
Studies in the Way of Words
Cambridge: Harvard University Press; 1989
http://www.hup.harvard.edu/catalog/GRISTU.html

HSL4114
Further proposals on medicines
Lancet 1989;2:752-753

HSL4115
Ginkgo biloba extract: over 5 million prescriptions a year
Lancet 1989;2:1513-1514

HSL4116
MaLAM’s open letter to industry
Scrip 1989(1457):23

HSL4117
Misuse of antidiarrhoeal medicines
Lancet 1989;2:995

HSL4118
Abate MA, Jacknowitz AI, Shumway JM.
Information sources utilized by private practice and university physicians
Drug Information Journal 1989;23:304-319

HSL4119
Adams DG.
FDA regulation of promotion of drugs: a legal primer
Drug Information Journal 1989;23:625-633

HSL4123
Barsan WG.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989;18:908

HSL4125
Beasley R, Crane J, Burgess C, Pearce N, Jackson R.
Fenoterol and severe asthma mortality
New Zealand Medical Journal 1989;102:294-295

HSL4126
Bell KD.
Regulating drug advertisements
Lancet 1989;2:678

HSL4128
Bressler R.
Endorsement of “patient promise” program
Lancet 1989;320:1355

HSL4129
Brickler EM.
Industrial marketing and medical ethics
New England Journal of Medicine 1989;320:1690-1692

HSL4130
Burton JL.
Baldness and minoxidil advertising
Lancet 1989;1:442-443

HSL4409
Finch KC.
To our readers: Publication guidelines for symposia
American Journal of Medicine 1989;86:A25-A26

HSL4410
Fogel ML.
Survey of pharmaceutical promotion in a family medicine training program
Canadian Family Physician 1989;35:1603-1605

HSL4411
Franaszek JB.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989;18:909

HSL4412
Franklin K.
The pharmaceutical tango
New Physician 1989;38(5):24-28

HSL4413
Freeman HL.
Supplement policy of the Journal
British Journal of Psychiatry 1989;155(6):6

HSL4414
Greenwood J.
Pharmaceutical representatives and the prescribing of drugs by family doctors
1989

HSL4415
Hanpadungdhama A.
Trials of dipyrone in Thailand
Lancet 1989;1:788

HSL4416
Hansson O
Inside Ciba-Geigy
Penang, Malaysia: International Organization of Consumers Unions; 1989

HSL4417
Harvey K.
Drug advertising
Medical Journal of Australia 1989;150:664-665

HSL4418
Harvey K.
What influences prescribing—scientific articles or promotional pressure?
Medical Journal of Australia 1989;150:282-283

HSL4419
The effect of journal advertising on market shares of new prescriptions
1989

HSL4422
Hershfield NB.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989;140:10

HSL4424
Holmes A, Wolfe S.
When a uniquely effective drug is teratogenic: the case of isotretinoin
New England Journal of Medicine 1989;321:756

HSL4429
Kreling DH, Szvimbo JW.
Drug information sources used by physicians and pharmacists: a study of public hospitals in Zimbabwe
Journal of Social and Administrative Pharmacy 1989;6:197-207

HSL4430
Kriegman AG.
Medical advice by celebrities
New England Journal of Medicine 1989;320:742

HSL4431
Krome RL.
Genentech, Inc, and symposium sponsorship
Annals of Emergency Medicine 1989;18:908-909

HSL4432
Kwok YS, Sylvan L.
Drug advertising
Medical Journal of Australia 1989;150:664

HSL4435
Lexchin J.
Doctors and detailers: therapeutic education or pharmaceutical promotion?
Int J Health Serv 1989;19(4):663-79

HSL4436
Mansfield PR.
MaLAM calls for better drug information
Essential Drugs Monitor 1989(8):9

HSL4437
Martin JH.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989;140:10

HSL4439
McSherry J.
Medifacts tape: response
Canadian Family Physician 1989;35:2219-2220

HSL4440
Mehta KK, Sorofman BA, Rowland CR.
Prescription drug advertising trends: a study of oral hypoglycemics.
Soc Sci Med 1989;29(7):853-7

HSL4441
Mitchell AD.
Baldness and minoxidil
Lancet 1989;1:910

HSL4442
Mitchell AA.
When a uniquely effective drug is teratogenic: the case of isotretinoin
New England Journal of Medicine 1989;321:757-758

HSL4443
Montagne M.
Social exchange, values, and the marketing of pharmaceuticals
Journal of Pharmaceutical Marketing & Management 1989;3(3):45-55

HSL4444
Morris LA, Mazis MB, Brinberg D.
Risk disclosures in televised prescription drug advertising to consumers
Journal of Public Policy & Marketing 1989;8:64-80

HSL4445
Neill JR.
A social history of psychotropic drug advertisements.
Soc Sci Med 1989;28(4):333-8

HSL4446
Rachlis M, Kushner C.
Second opinion: what’s wrong with Canada’s health-care system and how to fix it
1989

HSL4447
Randall H.
Drug promotional problems
Medical Journal of Australia 1989;150:743

HSL4449
Rosner F.
The ethics of accepting "free" gifts at conventions.
Cancer Invest 1989;7(3):295-6

HSL4454
Squires BP.
Continuing medical education: coming of age
Canadian Medical Association Journal 1989;140:491

HSL4455
Sriwatanakul K.
Trials of dipyrone in Thailand
Lancet 1989;1:788

HSL4458
Weir JH.
The arrhythmia consultation program
New England Journal of Medicine 1989;321:908

HSL4459
Wilson JD.
Fenoterol and severe asthma mortality
New Zealand Medical Journal 1989;102:295-296

HSL4460
Implementation of WHO’s revised drug strategy
1989

HSL4474
Morton P, Williamson RR.
Treatment of herpes zoster [reply]
New Zealand Medical Journal 1989;102:168

HSL4481
Roseman E.
Where the changing promotional mix is headed
Medical Marketing & Media 1989;24(6):10-13, 16, 18, 20

HSL4489
Antidiarrhoeals again under attack
Scrip 1989(1457):29

HSL4491
Huston P.
Those promotional dinners: food for thought?
Medical Marketing & Media 1989;24(12):78, 80, 82, 84, 86, 88, 90

HSL4495
Schwartz H.
In defence of US pharma promotion
Scrip 1989(1466):22-23

HSL4497
The basis of medical school cooperation with industry in the production of accredited continuing medical education
Journal of Continuing Education in the Health Professions 1989;10:373-375

HSL10175
Mehta KK, Sorofman BA, Rowland CR.
Prescription drug advertising trends: a study of oral hypoglycemics.
Soc Sci Med 1989;29(7):853-7

HSL10177
Brown EG.
Patient information leaflets from pharmaceutical companies: survey of leaflets submitted to the Department of Health
Pharmaceutical Medicine 1989;4(2):123-129

HSL10184
Oliver D.
Research on competition and regulation in the prescription drug market
Journal of Research in Pharmaceutical Economics 1989;1(1):28-32

HSL10206
Eklund LH.
Drug cost containment-the case for generics: situation in Sweden
Journal of Social and Administrative Pharmacy 1989;6(1):6-8

HSL4010
Kiatboonsri P, Richter J.
Unethical trials of dipyrone in Thailand.
Lancet 1988 Dec 24-31;2(8626-8627):1491

HSL10219
Collier J.
The cases for and against prescribing generic drugs: generic prescribing benefits patients.
BMJ 1988 Dec 17;297(6663):1596,
Link to source with long URL

HSL10220
Cruickshank JM.
The cases for and against prescribing generic drugs: don't take innovative research based pharmaceutical companies for granted.
BMJ 1988 Dec 17;297(6663):1597-8
Link to source with long URL

HSL2422
Landgren FT, Harvey KJ, Mashford ML, Moulds RF, Guthrie B, Hemming M.
Changing antibiotic prescribing by educational marketing.
Med J Aust 1988 Dec 5-19;149(11-12):595-9

HSL4113
Harvey K.
What influences prescribing--scientific articles or promotional pressure?
Med J Aust 1988 Dec 5-19;149(11-12):720

HSL10223
Denetclaw TH, Gomez D.
DEVELOPMENT OF A STUDENT/PHARMACIST SPEAKERS BUREAU
ASHP Midyear Clinical Meeting 1988 Dec;23

HSL10235
Guglielmo L, Ferrarese A, Castellani L, Carrara F.
Marketing, information and famotidine
Giornale Italiano di Farmacia Clinica 1988 Dec;1:133-137

HSL4112
Brief submitted to the Pharmaceutical Inquiry of Ontario
1988 Nov 28:10

HSL4015
Lexchin J.
Antihypertensive drugs and advertising.
N Z Med J 1988 Nov 23;101(858):805

HSL4111
Postmarketing surveillance - how should doctors get involved?
Drug and Therapeutics Bulletin 1988 Nov 14;26(3):89-91

HSL4073
Thompson WG.
The ethics of physician-pharmaceutical company relationships.
CMAJ 1988 Nov 1;139(9):835-6

HSL4108
Re: the promotion of erythromycin with bromhexine
1988 Nov

HSL4109
Direct-to-consumer advertising debated; APhA endorses some forms
American Pharmacy 1988 Nov;28(11):10-11

HSL4110
Danguilan MJ.
Drug commercials scored
Drug Monitor 1988 Nov;3(11):129-130

HSL10196
Direct-to-consumer advertising debated: APhA endorses some forms
American Pharmacy 1988 Nov;28:10-11

HSL10209
McRoberts KM.
Direct to consumer: new route for ethical drug marketers
Pharmaceutical Executive 1988 Nov;8:48, 51-52, 54, 56

HSL10218
Three drug manufacturers adopt JCPP stance on expiration dating
American Journal of Hospital Pharmacy 1988 Nov;45:2272, 2274, 2276

HSL10212
Weston DR.
Canada might mandate ingredient disclosure on labels
Drug Topics 1988 Oct 17;132:45

HSL4026
Musher DM.
Pharmaceutical company-sponsored symposia and medical ethics.
Am J Med 1988 Oct;85(4):596

HSL4105
Mann CC, Plummer ML.
The big headache
Atlantic Monthly 1988 Oct:39-46, 48-49, 52-57

HSL4106
Mitchell JF, Pawlicki KS.
"Dispense as written" advertisements are demeaning to pharmacists.
Am J Hosp Pharm 1988 Oct;45(10):2073

HSL4107
Rosenthal E.
Madison Avenue medicine
Discover 1988 Oct;9(10):34-36

HSL10200
Kushner D.
When pharmacists choose: Part 2
American Druggist 1988 Oct;198:82, 84, 86, 89-90, 95, 97-98,

HSL4034
Potter HP Jr.
Costs of drug advertising.
N Engl J Med 1988 Sep 22;319(12):798

HSL4103
Wells FO.
The code for promoting drugs.
BMJ 1988 Sep 10;297(6649):686-7

HSL4027
Nahata MC.
Drug package information in India.
Drug Intell Clin Pharm 1988 Sep;22(9):719

HSL4098
Editorial
Health Horizons 1988 Sep(5):2
www.ifpma.rog/hhhs/welcome.htm

HSL4099
IFPMA code: the breach and the observence
Health Horizons 1988 Sep(5):22-24
www.ifpma.rog/hhhs/welcome.htm

HSL4100
MaLAM letter follow up—Organon
MaLAM Newsletter 1988 Sep:1

HSL4101
Re: the promotion of Rogin E
1988 Sep

HSL10203
Lipman AG.
State of the pharmaceutical industry
Hospital Formulary 1988 Sep;23:689

HSL4009
Kaufman JL.
Profligate medical marketing.
N Engl J Med 1988 Aug 25;319(8):522

HSL4013
Langman M.
The code for promoting drugs.
BMJ 1988 Aug 20-27;297(6647):499-500

HSL4068
Shaughnessy AF.
Drug promotion in a family medicine training center.
JAMA 1988 Aug 19;260(7):926

HSL4076
Vo-kyung S, Ok KIM.
Investigation of the violations of pharmaceutical regulations in advertisements of children’s medicines
1988 Aug 18-20

HSL10230
Pearse WH.
Advertising of prescription drugs: 2
New England Journal of Medicine 1988 Aug 4;319:314

HSL4071
Storrs FJ.
Drug samples? A conflict of interest
Arch Dermatol. 1988 Aug 01;124(8):1283-5

HSL4102
PMAC Code of Marketing Practices: a programme of industry self-regulation
PMAC Insight 1988 Aug(21):1-5
www.canadapharma.org

HSL10217
Kaplan AH, Becker RH.
Sampling and the Prescription Drug Marketing Act of 1988
Pharmaceutical Executive 1988 Aug;8:54, 56

HSL4069
Smith EL.
Drug promotion in the Third World.
Lancet 1988 Jul 23;2(8604):224

HSL4066
Seibel J, Levitz SM.
Minorities in the Journal's advertisements.
N Engl J Med 1988 Jul 7;319(1):57-8

HSL10211
Weber LJ.
Getting ready for the Medicare drug benefit
Consultant Pharmacist 1988 Jul-Aug;3:303, 306

HSL4097
Re: the promotion of cefuroxime, cyanocobalamin, cephalexin, ranitidine and guaiphenesin
1988 Jun

HSL10216
Concerning the case of: United States v. American Pharmaceutical Association and Michigan State Pharmaceutical Association
Journal Michigan Pharmacist 1988 Jun;26:34-35

HSL10228
Innovation in drug sampling now being launched
Hospital Pharmacy 1988 Jun;23:576

HSL2345
World Health Organisation.
Ethical Criteria for Medicinal Drug Promotion
1988 May 13

HSL4093
Fisher DA.
The golden age of CME is yet to come [2nd of 3 letters]
JAMA 1988 May 6;259(17):2545

HSL4094
Madigan HS.
The golden age of CME is yet to come [1st of 3 letters]
JAMA 1988 May 6;259(17):2544-2545

HSL4095
Manning PR, Petit DW.
The golden age of CME is yet to come [reply]
JAMA 1988 May 6;259(17):2545-2546

HSL4096
Scarpinato L, Govaker D.
The golden age of CME is yet to come [3rd of 3 letters]
JAMA 1988 May 6;259(17):2545

HSL10215
Gebhart F.
California limits manufacturer liability in DES suit
Drug Topics 1988 May 2;132:44

HSL4078
Wein PJ, Hoffmann RP.
What really sells a drug today?
Hosp Pharm 1988 May;23(5):478-9

HSL4088
Healthcare communications and pharmaceutical promotion
Health Horizons 1988 May(4):16-17

HSL4089
The international industry discusses marketing standards
Health Horizons 1988 May(4):18-19

HSL4090
Re: the promotion of high dose oestradiol and progesterone and high dose oestradiol and testosterone
1988 May

HSL4091
Kaplar RT.
It's time to remove the brief summary from DTC print ads
Medical Marketing & Media 1988 May;33(5):44-46, 48

HSL4092
Williams JD.
Editorial
Health Horizons 1988 May(4):2

HSL10210
Laitin JA.
Sampling confusion: Prescription Drug Marketing Act of 1988
Pharmaceutical Executive 1988 May;8:60, 62, 64

HSL10227
Socha M.
Do you really know what you're dispensing?
Canadian Pharmaceutical Journal 1988 May;121:308-310

HSL10229
McCormick EM.
How drug sampling has become involved in drug diversion
Pharmacy Times 1988 May;54:134-137

HSL10232
Mossinghoff GJ.
Opposition to therapeutic interchange.
Am J Hosp Pharm 1988 May;45(5):1065

HSL1040
Mansfield P.
Diflunisal advertising.
Med J Aust 1988 Apr 18;148(8):418,

HSL4085
Anstice DW.
Diflunisal advertising [2nd of 2 replies]
Medical Journal of Australia 1988 Apr 18;148:418, 420

HSL4011
Krass M.
New code for drug makers tightens rules on drug samples, research.
CMAJ 1988 Apr 1;138(7):646

HSL4084
Good promotional practice (GPP)
Health Action International 1988 Apr
www.haiweb.org

HSL10226
Simonsen LL.
Top 200 drugs of 1987: new prescription volume increases 4.2% moving total Rxs up 1.4%
Pharmacy Times 1988 Apr;54:38-46

HSL10231
Illinois Supreme Court rules on third party liability for hospitals
American Journal of Hospital Pharmacy 1988 Apr;45:741-742

HSL10233
Fay JT.
Seeking self-reliance
Wholesale Drugs Magazine 1988 Apr-May;40:14

HSL4023
Miles S.
Searle's "Patient Promise".
N Engl J Med 1988 Mar 24;318(12):790

HSL10221
Roberts K, Sharp JR.
Original packs-what do patients think?
Pharmaceutical Journal 1988 Mar 19;240:382-384

HSL2454
Taylor SE, Brown JD.
Illusion and well-being: a social psychological perspective on mental health.
Psychol Bull 1988 Mar;103(2):193-210
http://content.apa.org/journals/bul/103/2/193

HSL10207
Top 50 generics of 1987
American Druggist 1988 Mar;197:83-84, 87

HSL10234
Segal R, Grines LL.
Prescribing authority for pharmacists as viewed by organized pharmacy, organized medicine, and the pharmaceutical industry.
Drug Intell Clin Pharm 1988 Mar;22(3):241-6

HSL10236
Penna PM.
Marketing formulary drug products: pharmacy-industry cooperation
American Journal of Hospital Pharmacy 1988 Mar;45:518

HSL10238
Brandon W.
Let the manufacturer explain increases.
Am Pharm 1988 Mar;NS28(3):6

HSL3994
Cohen EP.
Direct-to-the-public advertisement of prescription drugs.
N Engl J Med 1988 Feb 11;318(6):373-6

HSL4008
[No authors listed] Related Articles, Links Guidelines on postmarketing surveillance.
Joint committee of ABPI, BMA, CSM, and RCGP.
Br Med J (Clin Res Ed) 1988 Feb 6;296(6619):399-400

HSL4081
MaLAM letter follow up—Janssen
1988 Feb

HSL4082
Re: the promotion of penicillin/streptomycin combination
1988 Feb

HSL10224
Schwartz H.
Fee for service will never be outdated
Pharmaceutical Executive 1988 Feb;8:12, 14

HSL10225
Detels P.
Adding OTCs to ethicals: double markets or double trouble?
Pharmaceutical Executive 1988 Feb;8:43-44, 46

HSL4025
Murdoch JC.
An open assessment of tenoxicam in the treatment of acute gout in general practice.
N Z Med J 1988 Jan 27;101(838):21

HSL4079
Wells F.
Management of clinical trials.
Lancet 1988 Jan 16;1(8577):124

HSL4064
Rubin JN, Widerhorn J, Elkayam U.
Nitroglycerin tolerance.
N Engl J Med 1988 Jan 14;318(2):120

HSL4077
Weary PE.
Free drug samples: Use and abuse.
Arch Dermatol 1988 Jan 12;4(1):125-7

HSL2197
[No authors listed]
"A matter of influence": graduate medical education and commercial sponsorship.
N Engl J Med. 1988 Jan 7;318(1):52-4 1988 Jan 7;318(1):52-4

HSL4002
[No authors listed] Related Articles, Links Improving medical education in therapeutics.
Health and Public Policy Committee, American College of Physicians.
Ann Intern Med 1988 Jan;108(1):145-7

HSL4022
McLeod DC.
Pharmaceutical marketing--rewriting the textbook.
Drug Intell Clin Pharm 1988 Jan;22(1):62

HSL4080
Re: the promotion of vitamins A & E
1988 Jan

HSL10204
Harvey KJ.
Influence of advertising over prescribing
Australian Journal of Hospital Pharmacy 1988 Jan;18:25-27

HSL2198
Bowman MA, Pearle DL.
Changes in drug prescribing patterns related to commercial company funding of continuing medical education.
J Contin Educ Health Prof 1988;8(1):13-20

HSL3983
Breaches of Code of Pharmaceutical Marketing Practice
Lancet 1988;1:1179

HSL3984
International drug marketing code
Lancet 1988;1:988

HSL3985
International medical advertising
Lancet 1988;1:350

HSL3986
New marketing promotion guidelines for drug firms
Ontario Medical Review 1988;55(3):57-58

HSL3987
Post-marketing surveillance by drug manufacturers
Lancet 1988;2:977

HSL3988
Promoting health or promoting drugs? A HAI presentation on rational drug use
Health Action International 1988
www.haiweb.org

HSL3989
An unscrupulous advertisement
Lancet 1988;1:1098

HSL3990
Baldini R.
Nitroglycerin tolerance
New England Journal of Medicine 1988;318:120

HSL3991
Bone S, Wild R.
A glimpse before publication
Lancet 1988;1:1054

HSL3992
Boyle JA.
Searle’s “patient promise”
New England Journal of Medicine 1988;318:790

HSL3993
Cohen EP.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314-315

HSL3995
Collier J, Herxheimer A.
Medicines Act passes crucial test
Lancet 1988;1:1349

HSL3996
Ferguson A.
Commercial pharmaceutical medicine and medicalization: a case study from El Salvador
1988

HSL3997
Frishman W.
Pharmaceutical company-sponsored symposia and medical ethics
American Journal of Medicine 1988;85:597

HSL3998
Goldfinger S.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL3999
Harvey K.
The impact of the WHO ethical criteria for medicinal drug promotion: a study by Health Action International (HAI)
1988:4
www.haiweb.org

HSL4000
Harvey K.
The influence of advertising over prescribing
Australian Journal of Hospital Pharmacy 1988;18(3):25-28

HSL4001
Hawkins JW, Aber CS.
The content of advertisements in medical journals: distorting the image of women.
Women Health 1988;14(2):43-59

HSL4003
Heilman SR.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4004
Hemminki E.
Commercial information on drugs: confusing the physician?
Journal of Drug Issues 1988;18:245-257

HSL4005
Holloway WJ.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:New England Journal of Medicin

HSL4006
Hopley PJ, Rich AJ.
Pharmaceutical company representatives - an activity analysis
Pharmaceutical Journal 1988;241:R21-22

HSL4007
Hurwitz MA, Caves RE.
Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals
Journal of Law and Economics 1988;31:299-320

HSL4012
Kunin CM.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4014
Lefkowitz D.
Rap sheet on reps: the doctor will see you now
Pharmaceutical Executive 1988;8(6)

HSL4016
Lexchin J.
Introducing a new drug: an objection
Canadian Family Physician 1988;34:1009-1010

HSL4017
Lexchin J.
Pharmaceutical promotion in New Zealand.
Community Health Stud 1988;12(3):264-72

HSL4019
Marsh AA.
Junk mail
Canadian Medical Association Journal 1988;138:791

HSL4020
Masson A, Rubin PH.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314

HSL4021
McGregor M.
Pharmaceutical “generosity” and the medical profession
Annals of the Royal College of Physicians and Surgeons of Canada 1988;21:289

HSL4024
Mossinghoff GJ.
Costs of drug advertising
New England Journal of Medicine 1988;319:798

HSL4028
Osiobe SA.
Physicians’ and pharmacists’ drug information sources in Nigeria
Drug Information Journal 1988;22:553-563

HSL4029
Palmer WH, Ross DL.
Introducing a new drug: a response
Canadian Family Physician 1988;34:1010

HSL4030
Pearse WH.
Advertising of prescription drugs
New England Journal of Medicine 1988;319:314

HSL4031
Peay MY, Peay ER.
The role of commercial sources in the adoption of a new drug.
Soc Sci Med 1988;26(12):1183-9
Link to source with long URL

HSL4032
Pitt L, Nel D.
Pharmaceutical promotion tools—their relative importance
European Journal of Marketing 1988;22:7-14

HSL4033
Pleil AM, Pathak DS.
Commercial drug compendium information: a First World/Third World comparison.
Int J Health Serv 1988;18(4):587-602

HSL4060
Relman AS.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53-54

HSL4061
Relman AS.
Minorities in the Journal’s advertisements
New England Journal of Medicine 1988;319:58

HSL4062
Roizen R.
Why I oppose drug company payment of physician/investigators on a per patient/subject basis
IRB: a review of human subjects research 1988;10(1):9-10

HSL4063
Rosenblatt RA.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:52-53

HSL4065
Schiedermayer , McKinney WP.
The Feldene connection: drug dealing in the doctors’ parking lot?
New England Journal of Medicine 1988;319:1291-1292

HSL4067
Semple PF.
Disguised promotion of drugs
Lancet 1988;1:768

HSL4070
Sterky G, Tomson G, Sachs L, Henningsson B, Bergman U.
Medicines and society: a challenge in health development
1988

HSL4072
Tan M.
Dying for drugs: pill power and politics in the Philippines
1988

HSL4074
Tuthill JE.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53

HSL4075
Verma S.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:52

HSL4083
Scott JE.
Ad performance insights
Medical Marketing & Media 1988;23(2):32, 34, 36

HSL4086
Bell KD.
Diflunisal advertising [1st of 2 replies]
Medical Journal of Australia 1988;148:418

HSL4087
Mansfield PR.
Diflunisal advertising
Medical Journal of Australia 1988;148:418

HSL4104
Hardon A.
Towards rational drug-use in urban primary health care
Drug Monitor 1988;3(10):111-119

HSL4120
Anderson A.
Imovane (zopiclone)
New Zealand Medical Journal 1988;102:647

HSL4121
Arya T.
Popularize trade names through proper advertisements only and not through scientific articles
Journal of the Association of Physicians of India 1988;37:733

HSL4122
Attanasio AE.
Medical technology in Italy
Lancet 1988;2:109

HSL4124
Bass M.
Biased Medifacts tape: comment
Canadian Family Physician 1988;35:2219

HSL4168
World Health Organization.
Ethical Criteria for Medicinal Drug Promotion.
Geneva.: World Health Organization.; 1988
Link to source with long URL

HSL10186
Stoker A, Jeffery R.
Pharmaceuticals and health policy: an Indian example.
Soc Sci Med 1988;27(5):563-7

HSL10205
Legislation: pharmaceuticals and related products
International Digest of Health Legislation 1988;39(4):886-896

HSL10237
Hammond CM.
Peoples's choice: Part 2: Cashing in on consumer research
Pharmaceutical Executive 1988;8:44, 46, 48

HSL2722
Soumerai SB, Avorn J, Gortmaker S, Hawley S.
Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.
Am J Public Health 1987 Dec;77(12):1518-23
Link to source with long URL

HSL10239
AMA official OKs MD dispensing but rejects RPh prescribing
American Druggist 1987 Dec;197:28, 32, 36

HSL10243
Mossinghoff GJ.
How PMA companies have tightened their control of MD samples
Pharmacy Times 1987 Dec;53:55-57

HSL3884
Hampton JR, Julian DG.
Role of the pharmaceutical industry in major clinical trials.
Lancet 1987 Nov 28;2(8570):1258-9

HSL3873
Crook D.
Drug promotion.
N Z Med J 1987 Nov 25;100(836):725

HSL10245
Information for patients about medicines.
Lancet. 1987 Nov 7;2(8567):1077-8

HSL3893
Katz RA.
Unhook me.
J Am Acad Dermatol 1987 Nov;17(5)

HSL3934
Zuger A.
Promoting Retrovir.
N Engl J Med 1987 Oct 29;317(18):1160

HSL3886
Hardy AJ.
Drug promotion.
N Z Med J 1987 Oct 28;100(834):667

HSL10251
Revision of rules governing postmarketing reporting of adverse drug reactions
Federal Register 1987 Oct 13;52:37931-37936

HSL3981
Bell KD.
Drug advertising.
Med J Aust 1987 Oct 5;147(7):361

HSL3982
Wing LM, Moulds RF, Shenfield GM, Day RO.
Drug advertising [reply]
Medical Journal of Australia 1987 Oct 5;147:361

HSL3875
Finucane T.
Drug company-sponsored symposia: pros and cons.
Am J Med 1987 Oct;83(4):811-2

HSL3977
MaLAM letter follow up—Bayer
MaLAM Newsletter 1987 Oct

HSL3978
Re: the promotion of lincomycin and clindamycin
1987 Oct

HSL3979
Re: the promotion of trimethoprim/sulphamethoxazole/guaiphenesin/ammonium chloride
1987 Oct

HSL3980
Advertisement of Rx drugs to health professionals
1987 Oct:17

HSL10244
Chappell SC.
Among top 100 companies: 26 generic firms show aggregate 17% growth
Pharmacy Times 1987 Oct;53:63-64, 67-69

HSL3902
Lexchin J.
Drug promotion.
N Z Med J 1987 Sep 23;100(832):603

HSL3874
de Groot AC, Nater JP, Herxheimer A.
Minoxidil for male-pattern baldness.
Lancet 1987 Sep 5;2(8558):563

HSL3974
The IFPMA code: how it works and how it’s working
International Federation of Pharmaceutical Manufacturers Associations 1987 Sep
www.ifpma.rog/hhhs/welcome.htm

HSL3975
Re: the promotion of flunarizine
1987 Sep

HSL10249
McCarthy R.
Repackager sees $3 billion market
American Druggist 1987 Sep;196:62, 64

HSL10248
Denysyk OS.
Five-year prediction made for OTC products
Drug Topics 1987 Aug 17;131:64-65

HSL3772
Carter IE.
Canadian Psychiatric Association guidelines in relating to the pharmaceutical industry.
Can J Psychiatry 1987 Aug;32(6):476-86
http://www.cpa-apc.org/Publications/Position_Papers/Guideline.asp

HSL3869
Buckley EG.
Post-marketing surveillance of new drugs.
J R Coll Gen Pract 1987 Aug;37(301):337-8

HSL3967
Crane VS, Jefferson KK, Morgan R.
Rethinking pharmaceutical industry relationships.
Am J Hosp Pharm 1987 Aug;44(8):1884-6

HSL3970
DOH proposes regulating of drug ads
Drug Monitor 1987 Aug;2(8):3-5

HSL3971
Drug companies trying a facelift
Drug Monitor 1987 Aug;2(8):5-6

HSL3972
IFPMA code: trivial requirements ignored by companies
1987 Aug:1

HSL3973
Organon and anabolic steroids
WEMOS pharma group 1987 Aug

HSL3881
Graves J.
Frequent-flyer programs for drug prescribing.
N Engl J Med 1987 Jul 23;317(4):252

HSL3889
Hoppin ME.
A university perspective on pharmaceutical and industry support of research.
Am J Clin Nutr 1987 Jul;46(1)

HSL3911
Schweigert BS.
University-industry partnership in research.
Am J Clin Nutr 1987 Jul;46(1)

HSL3926
Weiss GB, Winslade WJ.
Is post-marketing drug follow-up research or advertising?
IRB 1987 Jul-Aug;9(4):10-1

HSL3968
Juergens JP.
Advertising in the American Journal of Hospital Pharmacy.
Am J Hosp Pharm 1987 Jul;44(7):1647-51

HSL3969
Zellmer WA.
Prudent and sensible advertising policies.
Am J Hosp Pharm 1987 Jul;44(7):1651-3

HSL10222
Alba Romero S
Pharmaceutical industry of Valencia: economic-health context of pharmaceutical specialties
Boletin de la Sociedad Espanola de Historia de la Farmacia 1987 Jul-Dec;38:401-408

HSL10241
Naude S.
Competition Board report
South African Pharmaceutical Journal 1987 Jul;54:199

HSL10246
Blauvelt BM, Erlanger DE.
Marketing in the Asian arena: Part 1
Pharmaceutical Executive 1987 Jul;7:36, 40, 44, 46, 48

HSL10267
George CF.
Telling patients about their medicines.
Br Med J (Clin Res Ed) 1987 Jun 20;294(6587):1566-7
Link to source with long URL

HSL2408
Mansfield PR.
Drug Advertising
Med J Aust 1987 Jun 15;146(12):660-661

HSL3894
Ketelbey JW.
Fenbufen trial in general practice.
N Z Med J 1987 Jun 10;100(825):361

HSL3901
Lexchin J.
Advertisement scrutiny.
Lancet 1987 Jun 6;1(8545):1323-4

HSL3868
Bower AD, Burkett GL.
Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices.
J Fam Pract 1987 Jun;24(6):612-6

HSL3888
Hilton D.
Promotion by the drug companies--should we accept their bribes?
J R Coll Gen Pract 1987 Jun;37(299):270

HSL3890
Hull FM, Marshall T.
Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians.
Fam Pract 1987 Jun;4(2):123-8

HSL3917
Speller DC.
The relationship between the Journal and the pharmaceutical industry.
J Antimicrob Chemother 1987 Jun;19(6):711-2

HSL3922
Thomas J 3rd.
National survey of hospital policies on pharmaceutical sales representatives' activities.
Am J Hosp Pharm 1987 Jun;44(6):1334-40

HSL3927
Wells F.
Promotion by the drug companies--the industry replies.
J R Coll Gen Pract 1987 Jun;37(299):270

HSL3964
MaLAM letter follow up—Janssen
MaLAM Newsletter 1987 Jun:1-2

HSL3965
MaLAM letter follow up—Parke-Davis
MaLAM Newsletter 1987 Jun:1

HSL3966
MaLAM letter follow up—Sandoz
MaLAM Newsletter 1987 Jun

HSL10257
Anderson LJ.
Dealing with the clash beween HMO MDs and pharmacists
Pharmaceutical Executive 1987 Jun;7:54, 56, 58, 60

HSL10266
Holland K.
Beecham Group Plc
Pharmaceutical Journal 1987 May 30;238:675-678

HSL3880
Goldfinger SE.
A matter of influence.
N Engl J Med 1987 May 28;316(22):1408-9

HSL3912
Seddon TD.
Drug promotion.
N Z Med J 1987 May 27;100(824):327

HSL10261
Enter the academic medical representative
Pharmaceutical Journal 1987 May 23;238:633

HSL3918
Spitzer WO, Hutchinson T, Lane D.
Postmarketing management of drug use: toward rational public policy.
CMAJ 1987 May 15;136(10):1022-4

HSL3900
Lauritsen K, Havelund T, Laursen LS, Rask-Madsen J.
Withholding unfavourable results in drug company sponsored clinical trials.
Lancet 1987 May 9;1(8541):1091

HSL3920
Stross JK.
Information sources and clinical decisions.
J Gen Intern Med 1987 May-Jun;2(3):155-9

HSL3962
IFPMA code advisers
International Federation of Pharmaceutical Manufacturers Associations 1987 May(1):5
www.ifpma.rog/hhhs/welcome.htm

HSL3963
Piroxicam
1987 May:1-7

HSL10256
Wertheimer AI.
Prescription drug advertising to the consumer in the United States
International Pharmacy Journal 1987 May-Jul;1:106-107

HSL10259
Concerning the case of: United States v. American Pharmaceutical Association and Michigan State Pharmaceutical Association, Civil No. G75-558 CA5, W.D. Michigan
Journal Michigan Pharmacist 1987 May;25:32-33

HSL3879
Godden JO.
Monitoring drug advertisements.
Lancet 1987 Apr 25;1(8539):980

HSL3887
Hay DR.
Drug promotion.
N Z Med J 1987 Apr 8;100(821):223

HSL3906
Marks I, Mathews A.
Treatment for panic.
Lancet 1987 Apr 4;1(8536):805

HSL10255
Madhavan S, Schondelmeyer SW.
Taking it over the counter: Part 1
Pharmaceutical Executive 1987 Apr;7:78, 80, 82

HSL10265
McCarthy R.
Tremors hit the drug chains
American Druggist 1987 Apr;195:34, 37-38, 40

HSL10240
Final report on branch resolutions
Pharmaceutical Journal 1987 Mar 28;238:415

HSL10272
Griffin JP, Sharp JR.
Original pack dispensing.
Br Med J (Clin Res Ed) 1987 Mar 21;294(6574):724-5
Link to source with long URL

HSL3899
Laurence DR.
The academic clinical pharmacologist and the Royal College of Physicians Report on the relationship between physicians and the pharmaceutical industry.
Br J Clin Pharmacol 1987 Mar;23(3):253-5

HSL3913
Shelley JH.
Relationships between physicians and the pharmaceutical industry: London Royal College of Physicians 1986.
Br J Clin Pharmacol 1987 Mar;23(3):257-8

HSL3961
Perri M, Nelson AA Jr.
An exploratory analysis of consumer recognition of direct-to-consumer advertising of prescription medications.
J Health Care Mark 1987 Mar;7(1):9-17

HSL10254
Phillips JH.
Dispensing with the RPh's services
American Druggist 1987 Mar;195:46-48

HSL10260
Jacknowitz AI.
Expiration dating and storage of drugs
US Pharmacist 1987 Mar;12:36, 38, 40, 106

HSL3959
Dyer C.
The penalties of issuing misleading advertisements.
Br Med J (Clin Res Ed) 1987 Feb 14;294(6569):426-7

HSL3960
Editor .
The penalties of issuing misleading advertisements [Editor's response]
British Medical Journal 1987 Feb 14;294:427

HSL3936
Double standards—some improvements
HAI News 1987 Feb(33):1-2, 12

HSL3937
MLAM letter follow up—Pfizer
1987 Feb:2

HSL3938
MLAM letter follow up—Scanpharm
1987 Feb:2

HSL3957
Re: the promotion of co-dergocrine
1987 Feb

HSL3958
Re: the promotion of loperamide
1987 Feb

HSL10253
Perri M.
Direct approach
Pharmaceutical Executive 1987 Feb;7:35, 38, 40, 42

HSL10270
PMA surveys MDs on sampling
American Druggist 1987 Feb;195:120

HSL3865
Pharmaceutical funds for clinical research: a mixed blessing.
Lancet. 1987 Jan 31;1(8527):257-8

HSL3929
Wilmshurst P.
An investigation by the ABPI (Association of the British Pharmaceutical Industry)
Lancet. 1987 Jan 10;1(8524):104

HSL3935
Hoechst a cause of illness? The pharmabusiness in the Third World
1987 Jan

HSL10263
Maddock PH.
Pharmacy in Colombia
International Pharmacy Journal 1987 Jan-Feb;1

HSL10273
Kaplan A, Becker R.
Labeling or scientific exchange
Pharmaceutical Executive 1987 Jan;7:56-58

HSL13980
Alba JW, Hutchinson JW.
Dimensions of Consumer Expertise
Journal of Consumer Research 1987 Jan;13(4):411-454
http://www.journals.uchicago.edu/doi/abs/10.1086/209080

HSL2414
Hutcheon L, Hutcheon M.
Medical “mythologies”: a semiotic approach to pharmaceutical advertising.
Queen's Q 1987;94:904-16
Nil

HSL2688
Blondeel L, Cannoodt L, DeMeyeere M, Proesmans H
Prescription behaviour of 358 Flemish general practitioners.
1987
Nil

HSL3863
Conviction for breach of Medicines Act in drug advertisement
Lancet 1987;1:57

HSL3864
Paediatricians get their skates on
Lancet 1987;2:735

HSL3866
Roussel appeal against advertisement decision
Lancet 1987;1:233

HSL3867
Bennett JC.
The reply
American Journal of Medicine 1987;83:812

HSL3870
Burley D, Parr G.
Role of the pharmaceutical industry in major clinical trials
Lancet 1987;2:1464-1465

HSL3871
Chotiner G.
Response
Journal of the American Academy of Dermatology 1987;17:866

HSL3872
Collier J, Herxheimer A.
Roussel convicted of misleading promotion
Lancet 1987;1:113-114

HSL3876
Fisherow WB.
The shape of prescription drug advertising: a survey of promotional techniques and regulatory trends
Food Drug Cosmetic Law Journal 1987;42:213-236

HSL3877
Freeman JW, Kaatz B.
The physician and the pharmaceutical detail man: an ethical analysis
Journal of Medical Humanities and Bioethics 1987;8:34-39

HSL3878
Gluck ME, Blumenthal D, Stoto MA.
University-industry relationships in life sciences: Implications for students and post-doctoral fellows
Research Policy 1987;16:327-336

HSL3882
Gray BV.
Drug promotion
New Zealand Medical Journal 1987;100:754

HSL3883
Greenhalgh T.
Drug prescription and self-medication in India: an exploratory survey.
Soc Sci Med 1987;25(3):307-18

HSL3885
Hancher L.
Regulating drug promotion: the UK experience
Journal of Consumer Policy 1987;10:383-407

HSL3891
Hutcheon L, Hutcheon M.
Medical “mythologies”: a semiotic approach to pharmaceutical marketing
Queen’s Quarterly 1987;94(4):904-916

HSL3892
Johnstone JM.
Special problems in direct-to-consumer advertising of prescription drugs
Food Drug Cosmetic Law Journal 1987;42:315-322

HSL3903
Lexchin J.
Pharmaceutical promotion in Canada: convince them or confuse them.
Int J Health Serv 1987;17(1):77-89

HSL3904
Lidstone J.
Marketing planning for the pharmaceutical industry
1987

HSL3905
Mahady JM.
Frequent-flyer programs for drug prescribing
New England Journal of Medicine 1987;317:252

HSL3907
Moulds RF, Wing IM, Shenfield GM, Day RO.
Drug advertising
Medical Journal of Australia 1987;147:160

HSL3908
Palmer WH, Ross DL.
Introducing a new drug into your practice
Canadian Family Physician 1987;33:2529-2533

HSL3909
Perri M, Dickson WM.
Direct to consumer prescription drug advertising: consumer attitudes and physician reaction
Journal of Pharmaceutical Marketing & Management 1987;2(1):3-25

HSL3910
Roberts WC.
Some realities of present-day cardiologic journal publishing in the USA.
Cardiology 1987;74(4):254-62

HSL3914
Singleton SW.
Promoting Retrovir
New England Journal of Medicine 1987;317:1160

HSL3915
Smith R.
In delicto flagrante
Medical Journal of Australia 1987;146:322-323

HSL3916
Smith RN.
Role of the pharmaceutical industry in major clinical trials
Lancet 1987;2:1464

HSL3919
Squires BP.
In whose service?
Canadian Medical Association Journal 1987;137:983

HSL3921
Szuba TJ.
Drug promotion under the magnifying glass
Journal of Social and Administrative Pharmacy 1987;4:77-80

HSL3924
Vere DW.
Advertising claims and the Medicines Act
Lancet 1987;1:278

HSL3925
Wall DW.
Ethics and the pharmaceutical industry: some ideas for general practitioners
Journal of the Royal College of General Practitioners 1987;37:267-269

HSL3928
Weston-davies WH.
Advertising claims and the Medicines Act
Lancet 1987;1:278

HSL3930
Wolffers I.
Drug information and sale practices in some pharmacies of Colombo, Sri Lanka.
Soc Sci Med 1987;25(3):319-21

HSL3933
Yellin AK.
FDA prescription drug enforcement policies and techniques
Food Drug Cosmetic Law Journal 1987;42:552-558

HSL3976
Tucker GK, Smith MC.
Direct-to-consumer advertising: Effects of different formats of warning information disclosure on cognitive reactions of adults
Journal of Pharmaceutical Marketing & Management 1987;2(1):27-41

HSL10242
Baum C, Faich GA, Anello C, Forbes MB.
Differences in manufacturer reporting of adverse drug reactions to the FDA in 1984
Drug Information Journal 1987;21(3):257-266

HSL3862
Griffin JP.
Conduct of research on amrinone.
Lancet 1986 Dec 20-27;2(8521-22):1462

HSL10268
White JP.
New prescription product lineup looking awesome
Drug Topics 1986 Dec 15;130:65-66, 68

HSL3780
Evans KR, Beltramini RF.
Physician acquisition of prescription drug information.
J Health Care Mark 1986 Dec;6(4):15-25

HSL3860
Re: the promotion of amidopyrine/phenylbutazone/prednisolone
1986 Dec

HSL14006
Evans KR, Beltramini RF.
Physician acquisition of prescription drug information
Journal of Health Care Marketing 1986 Dec;6(4):15-25

HSL3830
Wilmshurst P.
Policing the drug industry.
Lancet 1986 Nov 29;2(8518):1280-1

HSL10279
Anderson HJ.
More physicians dispensing commonly prescribed drugs.
Mod Healthc 1986 Nov 21;16(24):46

HSL10269
Robinson B.
Diversion bill derailed by sampling controversy
Drug Topics 1986 Nov 3;130:68

HSL3855
Doctors and the drug industry [Editor's response to 3rd letter (O'Dowd & Whibley)]
British Medical Journal 1986 Nov 1;293:1171

HSL3856
Fakes RW.
Doctors and the drug industry [2nd of 4 letters]
British Medical Journal 1986 Nov 1;293:1170-1171

HSL3857
Lenox-smith I, Clifford JM.
Doctors and the drug industry [4th of 4 letters]
British Medical Journal 1986 Nov 1;293:1171

HSL3858
O'Dowd TC, Whibley R.
Doctors and the drug industry [3rd of 4 letters]
British Medical Journal 1986 Nov 1;293:1171

HSL3859
Wilkie CE.
Doctors and the drug industry [1st of 4 letters]
British Medical Journal 1986 Nov 1;293:1170

HSL3852
MLAM letter follow up—Pfizer
MLAM Newsletter 1986 Nov

HSL3853
Re: the promotion of arsenic/strychnine
1986 Nov

HSL3854
Ford AR.
“When women outlive their ovaries”
New Internationalist 1986 Nov(165):12-13

HSL10271
Colombini A.
Health advertising
Notiz Chim Farm 1986 Nov;25:15

HSL10277
Wade RC.
Promotional group sessions: focus groups that sell
Pharmaceutical Executive 1986 Nov;6:32, 34

HSL3759
Where to draw the line.
Lancet. 1986 Oct 11;2(8511):849

HSL3822
Smith R.
Doctors and the drug industry: too close for comfort.
Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):905-6

HSL10258
Weiss B.
What's the FTC up to? State boards want to know!
Drug Topics 1986 Oct 6;130:32, 34

HSL3819
The relationship between physicians and the pharmaceutical industry: A report of the Royal College of Physicians.
J R Coll Physicians Lond 1986 Oct;20(4):235-42

HSL3849
MLAM letter follow up—Parke Davis/Warner Lambert
MLAM Newsletter 1986 Oct

HSL3850
Re: the promotion of oral streptomycin/chloramphenicol combination
1986 Oct

HSL3851
Greenhalgh T.
Beneath cosmetic reforms
HAI News 1986 Oct

HSL10278
Saks DF.
Today's trends to spur drug industry growth
US Pharmacist 1986 Oct;11:12-16, 20-22

HSL10280
Robinson B.
Dingell keeps fuse burning on sampling practices bomb
Drug Topics 1986 Sep 1;130:28-29

HSL10281
Weiss B.
Bar codes are here: Burroughs Wellcome makes first move
Drug Topics 1986 Sep 1;130:72

HSL3846
Re: the promotion of amrinone
1986 Sep

HSL3847
Re: the promotion of furazolidone/kaolin/pectin
1986 Sep

HSL3848
Lexchin J.
Good health?
New Outlook 1986 Sep-Oct:24-26, 28-31

HSL10252
Robbins J.
Pharmacy affairs: making the marketing connection
Pharmaceutical Executive 1986 Sep;6:40, 42, 44

HSL10275
Seltzer SM.
Electronic bulletin boards for RPh's will proliferate
American Druggist 1986 Sep;194:116, 119

HSL10286
Unfair sales act upheld
National Association of Retail Druggists Journal 1986 Sep;108:36-40

HSL10288
Vitriolic anti-generic campaigns held unwarranted
American Pharmacy 1986 Sep;26:16-17

HSL10274
Smith GT.
Use of generic medicines and importance of brand names. Part 2. Importance of brand names for pharmaceutical innovation
Pharmaceutical Journal 1986 Aug 30;237:242-243

HSL3814
Musher DM, Young EJ, Hamill RJ.
The ethics of pharmaceutical promotion.
N Engl J Med 1986 Aug 28;315(9):590

HSL3786
Holmes J, Hornblow A, Logan W, Botting C, Wells E, Tan SP, Chetwynd J, Frampton C.
Offensive advertising?
N Z Med J 1986 Aug 27;99(808):641-2

HSL3827
Taylor D.
Effects of medical research on life expectancy.
Lancet 1986 Aug 16;2(8503):399-400

HSL3825
St George D.
Life expectancy, truth, and the ABPI.
Lancet 1986 Aug 9;2(8502):346

HSL3813
Moulds RF, Bochner F, Wing LM.
Drug advertising.
Med J Aust 1986 Aug 4-18;145(3-4):178-9

HSL10284
Robinson B.
Industry moves to control its own sampling destiny
Drug Topics 1986 Aug 4;130:22

HSL3841
Re: the promotion of piroxicam
1986 Aug

HSL3842
Shugar GS.
Mixed opinions on direct-to-consumer advertising
Medical Marketing & Media 1986 Aug;21(8):36-38, 40-41

HSL10283
Shugar GR.
Mixed opinions on direct-to-consumer advertising
Medical Marketing and Media 1986 Aug;21:37-38, 40-41

HSL10287
Davis DA.
FDA becoming sensitive to anti-generic campaign
Drug Cosmet Ind 1986 Aug;139:30, 32, 35

HSL10290
Hadeler F.
Should expiration dates be required on patients' prescription labels?
Am Pharm 1986 Aug;NS26(8):30-5

HSL10293
De-mino L.
How Peoples Drug chain helps patrons take medicines properly
Pharmacy Times 1986 Aug;52:36-38

HSL10264
Harvey KJ, Stewart R, Hemming M, Naismith N, Moulds RF.
Educational antibiotic advertising.
Med J Aust 1986 Jul 7;145(1):28-32

HSL3839
Re: the promotion of diphenhydramine and ammonium chloride
1986 Jul

HSL3840
Pierpaoli PG.
ASHP's position on direct-to-consumer advertising of prescription drug products.
Am J Hosp Pharm 1986 Jul;43(7):1763-5

HSL10294
Programmed-delivery products revitalize markets for old drugs, report says
American Journal of Hospital Pharmacy 1986 Jul;43:1645-1646

HSL10297
Commodity generic sales in 1985 grew 50% over 1984, says report on generic drug industry
American Journal of Hospital Pharmacy 1986 Jul;43:1644

HSL10302
Concerning the case of: United States v. American Pharmaceutical Association and Michigan State Pharmaceutical Association, Civil No. G75-558 CA5, W.D. Michigan
Journal Michigan Pharmacist 1986 Jul;24:14-15

HSL3783
Greenhalgh T.
Drug marketing in the Third World: beneath the cosmetic reforms.
Lancet 1986 Jun 7;1(8493):1318-20

HSL10292
Cusick JJ, Downs GE.
Prescription to over-the-counter switch
American Druggist 1986 Jun;193:101-107, 113

HSL10295
McCarthy R.
Dingell subcommittee would ban physical sampling
American Druggist 1986 Jun;193:12, 17

HSL3778
Davidson RA.
Source of funding and outcome of clinical trials.
J Gen Intern Med 1986 May-Jun;1(3):155-8

HSL10282
Lord R.
Reye's syndrome and aspirin-industry's position
Australian Journal of Pharmacy 1986 May;67:518, 520, 522

HSL10309
Cardinale V.
Industry leaders extend hand in fair pricing
Drug Topics 1986 Apr 21;130:18, 20, 22

HSL3807
McCue JD, Hansen CJ, Gal P.
Physicians' opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information.
South Med J 1986 Apr;79(4):441-3

HSL3837
Re: the promotion of Rheopyrine
1986 Apr

HSL10276
Woodhouse RJ.
UK prescribing limits begin to take toll
Drug Cosmet Ind 1986 Apr;138:50, 52, 104-105

HSL10301
FDA speaks out about generic drug quality
National Association of Boards of Pharmacy Newsletter 1986 Apr;15:53-54

HSL10306
Commerce Department predicts gains in pharmacist prescribing
American Pharmacy 1986 Apr;26:20

HSL10310
Mossinghoff GJ.
Drug price increase explained.
Am Pharm 1986 Apr;NS26(4):5-6

HSL10300
Drug search: meshing costs, regs
Medical World News 1986 Mar 10;27:114-115

HSL3823
Spiro HM.
Mammon and medicine. The rewards of clinical trials
JAMA. 1986 Mar 7;255(9):1174-5 1986 Mar 07;255(9):1174-5

HSL3835
Re: the promotion of Primobolan and Fortabol
1986 Mar

HSL3836
To what extent should pharmaceutical houses advertise to the public?
Pharmacy Times 1986 Mar;52(3):86-88, 90, 93

HSL10303
Kushner D.
Don't advertise Rx drugs to public, mfrs are urged
American Druggist 1986 Mar;193:126, 128, 130, 132

HSL10318
To what extent should pharmaceutical houses advertise to the public?
Pharmacy Times 1986 Mar;52:86-88, 90, 93

HSL10317
Robinson B.
Consumer Rx ads viewed warily by pharmacists
Drug Topics 1986 Feb 17;130:94, 96

HSL10315
Robinson B.
Consumer Rx ads edge closer to reality
Drug Topics 1986 Feb 3;130:42

HSL3834
Re: the promotion of ibuprofen syrup
1986 Feb

HSL10291
Radoczy G.
Formulae Normales
Gyogyszereszet 1986 Feb;30:59-62

HSL10311
Cramer PK.
Measuring the marketing clout of postmarketing clinical studies
Pharmaceutical Executive 1986 Feb;6:54-55, 57

HSL10316
To keep drugs cost effective, industry told to look at compliance
American Pharmacy 1986 Feb;26:7

HSL3803
Mahood CB, Rothwell RP, Holford N.
Slow-release theophylline (THEO-24)
N Z Med J. 1986 Jan 22;99(794):21

HSL10308
Debenedette V.
CBS ready for Rx ads
Med Advert News 1986 Jan 15;5:1, 37-38

HSL1041
Mansfield P.
Phenylbutazone.
Med J Aust 1986 Jan 6;144(1):55

HSL3931
Woods D.
Annual report to the readers
Canadian Medical Association Journal 1986 Jan 01;136(1):7

HSL3811
Morris LA, Brinberg D, Klimberg R, Rivera C, Millstein LG.
The attitudes of consumers toward direct advertising of prescription drugs.
Public Health Rep 1986 Jan-Feb;101(1):82-9

HSL3833
How physicians feel about Rx drug product ads beamed at the public
Pharmacy Times 1986 Jan;52(1):85-88, 91-92

HSL8992
How physicians feel about Rx drug product ads beamed at the public
Pharmacy Times 1986 Jan;52:85-88, 91-92

HSL10247
Pollock CL.
Advertising prescription drugs to the public: who benefits?
DO 1986 Jan;27:111-116

HSL10250
Sandrick K.
Generics: moving in on the prescription drug market
DO 1986 Jan;27:85-88

HSL10304
Discriminatory pricing: attacking prescription drug diversion at its source
National Association of Retail Druggists Journal 1986 Jan;108:16-18, 28

HSL2413
Goldman R, Montagne M.
Marketing 'mind mechanics': decoding antidepressant drug advertisements.
Soc Sci Med 1986;22(10):1047-58
Nil

HSL3755
Bayer UK Ltd suspended over actions by representatives
Pharmaceutical Journal 1986;237:821-822

HSL3756
Charges against Roussel Laboratories concerning advertisements
Lancet 1986;1:112

HSL3757
Congressional panel wants to ban drug samples
Canadian Medical Association Journal 1986;134:1302

HSL3758
Need for a rational drugs policy
Lancet 1986;1:262

HSL3760
Akin GM.
The ethics of pharmaceutical promotion
New England Journal of Medicine 1986;315:590

HSL3761
Anand MP.
Marketing drugs in the Third World
Lancet 1986;2:222

HSL3762
Bader M.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523

HSL3763
Bearn AG.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974

HSL3764
Bhattacharjee PK.
Marketing drugs in the Third World
Lancet 1986;2:576

HSL3765
Blum AL, Chalmers TC, Deutsch E, Koch-weser J, Langman M, Rosen A, Tygstrup N, Zentgraf R.
Differing attitudes of industry and academia towards controlled clinical trials
European Journal of Clinical Investigation 1986;16:455-460

HSL3766
Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D.
University-industry research relationships in biotechnology: implications for the university
Science 1986;232:1361-1366

HSL3768
Burley DM.
Should a drug company employee edit a medical journal?
Lancet 1986;1(801)

HSL3769
Cairns L.
Offensive advertising?
New Zealand Medical Journal 1986;99:641-642

HSL3771
Guidelines for drug-company-supported CME
Canadian Medical Association Journal 1986;135:384A

HSL3773
Cohen RL.
Drug companies and journal supplements
Lancet 1986;1:1157

HSL3774
Collins GL.
Prescription drug advertising: a medical view
Journal of Pharmaceutical Marketing & Management 1986;1(2):19-22

HSL3775
Comanor WS.
The political economy of the pharmaceutical industry.
J Econ Lit 1986;24(3):1178-1217

HSL3776
Drugs and the Third World: chloroform sale and hazards—a Malaysian study
Consumers’ Association of Penang 1986

HSL3777
Cramer R.
Information responsibilities of generic drug companies
American Journal of Hospital Pharmacy 1986;43:1674-1675

HSL3779
Dingell JD.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524

HSL3781
Feather KR.
Direct to the consumer advertising—how close can we come?
Journal of Pharmaceutical Marketing & Management 1986;1(2):67-71

HSL3784
Greenhalgh T.
Marketing drugs in the Third World
Lancet 1986;2:222

HSL3785
Henderson AM.
The CBS consumer model
Journal of Pharmaceutical Marketing & Management 1986;1(2):7-11

HSL3787
Kerr HD, Brobny EC.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523-524

HSL3793
Lapinski F.
Omission of women and black physicians from Journal ads
New England Journal of Medicine 1986;314:653

HSL3798
Lavizzo-mourey R.
Medications and the elderly
Journal of Pharmaceutical Marketing & Management 1986;1(2):45-50

HSL3799
Lee A.
Marketing drugs in the Third World
Lancet 1986;2:222

HSL3800
Leigh AP.
Should a drug company employee edit a medical journal?
Lancet 1986;1:974

HSL3801
Lipton C.
Consumer advertising and pharmaceuticals: a happy marriage?
Journal of Pharmaceutical Marketing & Management 1986;1(2):23-28

HSL3802
Mac Sheoin T.
Unethical behavior in an ethical industry? Critical coverage of the pharmaceutical industry, 1983-1984
International Journal of Health Services 1986;16:141-162

HSL3804
Mamdani M, Walker G.
Essential drugs in the developing world
Health Policy and Planning 1986;1:187-201

HSL3805
Masson A, Rubin PH.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524

HSL3806
Masson A, Rubin PH.
Warning: brief summaries may be hazardous to your health (and wealth) or the real issues in prescription drug advertising to consumers
Journal of Pharmaceutical Marketing & Management 1986;1(2):29-43

HSL3808
McGovern I.
Advertising and benzodiazepines
Medical Journal of Australia 1986;145:179

HSL3809
McMahon FG.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:524

HSL3810
Moench EA.
The Boots advertising campaign
Journal of Pharmaceutical Marketing & Management 1986;1(2):51-55

HSL3812
Morris LA, Brinberg D, Klimberg R, Millstein L, Rivera C.
Consumer attitudes about advertisements for medicinal drugs.
Soc Sci Med 1986;22(6):629-38

HSL3815
O’brien M.
Advertising prescription drugs to the public
New England Journal of Medicine 1986;314:523

HSL3816
Perkin RL.
The pharmaceutical industry
Canadian Family Physician 1986;32:2013

HSL3817
Rockwell T.
The Lifetime experience with prescription drug advertising exposed to consumers
Journal of Pharmaceutical Marketing & Management 1986;1(2):13-18

HSL3818
Roseman EP.
Checking the scorecard
Medical Marketing & Media 1986;21(10):40, 42, 44

HSL3820
Schueler KR.
Direct-to-consumer promotion
Journal of Pharmaceutical Marketing & Management 1986;1(2):57-65

HSL3821
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986;16(4):659-67

HSL3824
St. George
Effects of medical research on life expectancy
Lancet 1986;2:517

HSL3826
Stavem P.
Should a drug company employee edit a medical journal?
Lancet 1986;1:684

HSL3828
Turner J.
Antibiotic conference cancelled for second time
Lancet 1986;1:333

HSL3829
Vener AM, Krupka LR.
Over-the-counter drug advertising in gender oriented popular magazines.
J Drug Educ 1986;16(4):367-81

HSL3831
Woods D.
Annual report to the readers
Canadian Medical Association Journal 1986;134:7

HSL3832
Woods D.
PMAC to spend almost $1 million annually to reach “stakeholders”
Canadian Medical Association Journal 1986;134:1387, 1389

HSL3838
Rothschild M.
Death by prescription
The Progressive 1986;50(6):18, 20-22

HSL3861
Collier J.
Promotion of medicines—the failure of regulation
Medicine in Society 1986;12(3):8-10

HSL9709
McDonnell K
Adverse Effects - Women and the Pharmaceutical Industry
: Canadian Scholars Press; 1986
Link to source with long URL

HSL10262
Laroche M, Rosenblatt J, Wahler L, Bliemel F.
Economic considerations for dispensing pharmacists: the impact of price-quality evaluations on brand categorization.
J Pharm Mark Manage 1986 Fal;1(1):41-60

HSL10285
Von-breitenbach G.
German pharmaceutical industry abroad. Part 2
Drugs Made in Germany 1986;29(2):63-67

HSL10289
Lowenthal W, Klein WS 3rd, Overton CP.
Thinking about ethical dilemmas in pharmacy.
Am J Pharm Educ 1986 Sum;50(2):161-4

HSL10305
Morris LA, Brinberg D, Klimberg R, Millstein L, Rivera C.
Consumer attitudes about advertisements for medicinal drugs.
Soc Sci Med 1986;22(6):629-38

HSL14017
Holbrook MB, Lehmann DR, O'Shaughnessy J.
Using versus Choosing: The Relationship of the Consumption Experience to Reasons for Purchasing.
European Journal of Marketing 1986;20(8):49-62
http://www.ingentaconnect.com/content/mcb/007

HSL10324
Robinson B.
PMA chief sees pattern of cooperation with pharmacy
Drug Topics 1985 Dec 9;129:12-13

HSL3753
Re: the promotion of Entero-Sediv
1985 Dec 01

HSL10323
Jacknowitz AI.
Inactive ingredients in medications
US Pharmacist 1985 Dec;10:37, 58

HSL10325
Shepherd MD.
Managing your pharmacy: targeting your elderly market
American Druggist 1985 Dec;192:49, 51-53, 56

HSL10314
Dunn WR, Hamilton DD, Lilja J.
Pharmacy in Sweden
Pharmaceutical Journal 1985 Nov 30;235:714-715

HSL10319
Pack size changes and six month delay planned
Pharmaceutical Journal 1985 Nov 30;235:712

HSL3750
Re: the promotion of anabolic steroids for children
1985 Nov 01

HSL3751
FDA withdraws moratorium on direct-to-consumer advertising
American Pharmacy 1985 Nov 01;25(11):9-11

HSL3752
Teplitsky B.
A 30-year trend: what chief pharmacists think about detailers.
Pharm Times 1985 Nov;51(11):83-92

HSL8991
Cronin WF.
Marketing to the new decision makers
Pharmaceutical Executive 1985 Nov;5:48, 50, 53

HSL8994
Printer technology: the new impact
ComputerTalk for the Pharmacist 1985 Nov;5:16-19, 22-25

HSL9006
FDA withdraws moratorium on direct to consumer advertising
American Pharmacy 1985 Nov:9-11

HSL10313
Original pack dispensing by 1987?
Pharmaceutical Journal 1985 Oct 26;235:569-570

HSL9009
Robinson B.
Rx-to-consumer advertising debate starts up again
Drug Topics 1985 Oct 7;129:20, 22

HSL3721
Logan AG, Larochelle P.
Diuretic-induced hypokalemia in hypertension.
CMAJ 1985 Oct 1;133(7):639-40

HSL3729
Osiobe SA.
Sources of information for biomedical decision-making.
Methods Inf Med 1985 Oct;24(4):225-9

HSL3749
Morris LA, Ruffner M, Klimberg , R .
Warning disclosures for prescription drugs
Journal of Advertising Research 1985 Oct-Nov;25(2):25-32

HSL8998
Buono LC, Hartmann JP.
Hybrids new OTC option
Pharmaceutical Executive 1985 Oct;5:46, 48, 52

HSL8999
Muglia D.
Hispanic U.S.A.-undiscovered market
Pharmaceutical Executive 1985 Oct;5:66, 68, 70

HSL9011
Changes in drug marketing bode well for pharmacy
American Pharmacy 1985 Oct:22

HSL10299
Industrial drug research in seven nations: key findings of a recent OHE/MPS study on the drug industry in seven OECD-countries
Drugs Made in Germany 1985 Oct-Dec;25:153-158, 160

HSL3715
Harvey K, Darvall L.
Australian pharmaceutical advertising: a critique.
Med J Aust 1985 Sep 30;143(7):272-4

HSL3734
Weissel JR.
Australian pharmaceutical advertising: the industry's view.
Med J Aust 1985 Sep 30;143(7):274-5

HSL3652
Relman AS.
Dealing with conflicts of interest.
N Engl J Med 1985 Sep 19;313(12):749-51

HSL1042
Mansfield P.
Phenylbutazone.
Med J Aust 1985 Sep 2;143(5):219-20

HSL3748
Re: the promotion of vitamins A & E
1985 Sep 01

HSL8993
Concerning the case of: United States v. American Pharmaceutical Association and Michigan State Pharmaceutical Association, Civil No. G75-558 CA5, W.D.
Journal Michigan Pharmacist 1985 Sep;23:14-15

HSL9005
Gross A.
TV or not TV? it's more than one question
Pharmaceutical Executive 1985 Sep;5:50, 52, 54

HSL9014
Schlegel expresses pharmacist concerns over differential pricing, inflation
American Pharmacy 1985 Sep:6-7

HSL10312
Wasserman MD.
Worldwide maintenance of drug product quality
Drug Cosmet Ind 1985 Sep;137:35, 38, 40

HSL10321
Dickinson J.
United States diversion schemes threaten integrity of US prescription drugs
Pharmaceutical Journal 1985 Aug 3;235:144-145

HSL3747
Re: the promotion of tetracycline
1985 Aug 01

HSL3716
Jefferis JE.
The pharmaceutical industry and academic medicine: opportunities for physician collaboration.
Circulation 1985 Aug;72(2)

HSL3717
Kaplan NM.
Educating physicians in the use of pharmaceuticals.
Circulation 1985 Aug;72(2)

HSL9004
Goldstein GS.
Corporate communication strategies-prescription from a medical director
Pharmaceutical Executive 1985 Aug;5:54-56

HSL3728
Murphy PA.
One drug company's sales techniques.
N Engl J Med 1985 Jul 25;313(4):270

HSL9013
Robinson B.
Pharmacists see need for controls on Rx sampling
Drug Topics 1985 Jul 15;129:12-14

HSL3726
Miller K, Gouveia WA, Barza M, Bower K, Curtis L, Decker EL, Dorkin H, Estes M, Mackey W, Marchbein D, et al.
Undesirable marketing practices in the pharmaceutical industry.
N Engl J Med 1985 Jul 4;313(1):54

HSL9001
Kaplan A, Becker R.
FDA and the single-sponsor journal
Pharmaceutical Executive 1985 Jul;5:48-49

HSL9012
Danielson DA.
Influencing the physician-drug industry strategies
Generics 1985 Jul;1:32-34, 37-40, 42-43

HSL10298
O'Sullivan PJ.
Generic medicines: a prescription for decline
Irish Pharmaceutical Union Review 1985 Jul-Aug;10:241-242, 244, 246-247

HSL10320
ABPI code of practice committee: seven complaints upheld (three of them against Lederle)
Pharmaceutical Journal 1985 Jun 22;234:782-783

HSL3745
Gould D.
Funds that can foster suspicion
New Scientist 1985 Jun 13;106:30

HSL3742
Re: the promotion of pizotifen
1985 Jun 01

HSL3746
Re: the promotion of ampicillin (Binotal) in Indonesia
1985 Jun 01

HSL2729
Willams P.
Sound Impressions
Pharmaceutical Executive. 1985 Jun:58-59
Nil

HSL3743
Mansfield PR.
Protecting the innocent from harm: the Medical Lobby for Appropriate Marketing (MLAM)
New Doctor 1985 Jun(36):22-24

HSL10322
Labson D.
Measuring the effectiveness of nonjournal media
Pharmaceutica Executive 1985 Jun;5:48-51

HSL10327
Williams PC.
Sound impressions
Pharmaceutical Executive 1985 Jun;5:58-59

HSL10307
Crossen DK.
Providing just what the doctor ordered
Pharmaceutical Executive 1985 May;5:84-85

HSL10326
Kissel S, Flaum S.
There's a bit of consumer in every M.D.
Pharmaceutical Executive 1985 May;5:54, 56-57

HSL3741
Sivarajan M.
Tarnishing the medical profession's image.
N Engl J Med 1985 Apr 25;312(17):1132

HSL3740
MLAM letter update
MLAM Newsletter 1985 Apr 01

HSL3767
Bowman MA.
The impact of the expanding supply of physicians on continuing medical education.
Mobius 1985 Apr;5(2):28-31

HSL9019
Pharmaceuticals have flat year-with exceptions
American Druggist 1985 Apr;191:154

HSL9022
Limited list: PM attacks ABPI advertisement
Pharmaceutical Journal 1985 Mar 9;234: 297

HSL3738
MLAM in the medical media
MLAM Newsletter 1985 Mar 01

HSL3739
Kunin CM.
The responsibility of the infectious disease community for the optimal use of antimicrobial agents.
J Infect Dis 1985 Mar;151(3):388-98

HSL8997
Wicker WV, Dingell JD.
Prescription drug advertising to consumers
Pharmaceutical Executive 1985 Mar;5:61-62

HSL9007
Millstein LG.
What price drug advertising?
Pharmaceutical Executive 1985 Mar;5:56, 59

HSL9008
Shuler J.
Eliminating the ambiguities
Pharmaceutical Executive 1985 Mar;5:13

HSL3722
Loshak D.
Anti-inflammatory drugs under fire.
Lancet 1985 Feb 16;1(8425):410

HSL3732
Smith R.
Doctors and the drug industry in Sweden.
Br Med J (Clin Res Ed) 1985 Feb 9;290(6466):448-50

HSL9032
Limited list: facts and fallacies rebutted
Pharmaceutical Journal 1985 Feb 9;234:164-165

HSL9027
Limited list prescribing: Society's comments on Minister's provisional list
Pharmaceutical Journal 1985 Feb 2;234:146-149

HSL3709
Bland JM, Jones DR, Bennett S, Cook DG, Haines AP, MacFarlane AJ.
Is the clinical trial evidence about new drugs statistically adequate?
Br J Clin Pharmacol 1985 Feb;19(2):155-60

HSL8996
Rose M, Merk P.
Forecasting-when history does not repeat itself
Pharmaceutical Executive 1985 Feb;5:36-38, 72

HSL9002
Boggs D, Clarke DG.
Predicting product potential
Pharmaceutical Executive 1985 Feb;5:31-32, 35

HSL9003
Schwartz H.
Blocking the industry's fast lane
Pharmaceutical Executive 1985 Feb;5:13-14

HSL9020
Cooper P.
Limiting the prescriber
Irish Pharmacy Journal 1985 Feb;63:59-60

HSL3737
Re: the promotion of Lomotil
1985 Jan 01

HSL9024
Congressional report advises against prescription drug ads to consumers
American Pharmacy 1985 Jan:18

HSL2460
Woolgar S, Pawluch D.
Ontological gerrymandering: The anatomy of social problems explanations.
Social Problems 1985;32:214-27
http://pos.sagepub.com/cgi/content/refs/35/2/175

HSL2507
Ferry ME, Lamy PP, Becker LA.
Physicians' knowledge of prescribing for the elderly. A study of primary care physicians in Pennsylvania.
J Am Geriatr Soc 1985;33:616-21

HSL1560
Goleman D.
Vital lies, simple truths: The psychology of self-deception.
London: Bloomsbury; 1985
Link to source with long URL

HSL3705
The battle over physicians’ samples
Lancet 1985;2:1001

HSL3706
WHO meeting agrees on rational drugs strategy
Lancet 1985;2:1350-1351

HSL3707
Bateman DN.
Ethics of drug marketing
Lancet 1985;1:166

HSL3708
Benseman J.
The great paper waste: the use of unsolicited medical literature by general practitioners
New Zealand Family Physician 1985;12:96-98

HSL3710
Collier J.
Ethics of drug marketing
Lancet 1985;1:166-167

HSL3711
Curran V, Golombok S.
Bottling it up
1985

HSL3712
Dasco CC.
A physician/medical industrial ethos
American Journal of Medicine 1985;79:675

HSL3713
Eastman HC.
Report of the commission of inquiry on the pharmaceutical industry
1985

HSL3718
Krupka LR, Vener AM.
Prescription drug advertising: trends and implications.
Soc Sci Med 1985;20(3):191-7

HSL3719
Lefever R.
Market research in sheep’s clothing
Lancet 1985;1:760

HSL3720
Lexchin J.
Diuretic-induced hypokalemia in hypertension
Canadian Medical Association Journal 1985;133:183

HSL3723
Mackowiak JI, Gagnon JP.
Effects of promotion on pharmaceutical demand.
Soc Sci Med 1985;20(11):1191-7

HSL3724
Magor G.
Who sends junk mail?
Canadian Family Physician 1985;31:911

HSL3725
Masson A, Rubin PH.
Matching prescription drugs and consumers: The benefits of direct advertising.
New England Journal of Medicine 1985;313:513-515

HSL3727
Mintz M.
At any cost: corporate greed, women, and the Dalkon Shield
1985

HSL3730
Osiobe SA.
Use of information resources by health professionals: a review of the literature.
Soc Sci Med 1985;21(9):965-73

HSL3731
Putnam RW, Fox RD, Mazmanian PE.
Report to Pharmaceutical Manufacturers Association of Canada: an analysis of drug prescribing changes by physicians
1985

HSL3733
Van DER.
Marketing myths: selling drugs in the Third World
Medicine in Society 1985;2(2):41-45

HSL3735
Woods D.
Annual report to the readers
Canadian Medical Association Journal 1985;132:7

HSL3736
Woods D, Radford T.
Annual meeting 1985
Canadian Medical Association Journal 1985;133:591-594, 597

HSL8995
Haverkost LF.
How industry assesses and picks suitable candidates for switch
Drug Information Journal 1985;19(2):133-138

HSL9000
Hutt PB.
Drugs for self-medication in the future: their source and the social, political, and regulatory climate
Drug Information Journal 1985;19(2):195-199

HSL9010
Guerard C.
Impact of advertising and its regulation: Federal Trade Commission perspective
Drug Information Journal 1985;19(2):163-172

HSL14029
Monroe KB, Krishnan R.
Effect of Price on Subjective Product Evaluations
Jacoby J, Olson JG. Perceived Quality New York: Lexington Books; 1985
Link to source with long URL

HSL12182
Drug Maker Pleads Guilty Over Lethal Side Effects
Associated Press 1984 Dec 14
Link to source with long URL

HSL9026
White JP.
Prescriptions: growth, gyrations, generics
Drug Topics 1984 Dec 10;128:46, 48-49, 52

HSL9035
Limited list prescribing: ABPI begins campaign against stupid and dangerous proposal
Pharmaceutical Journal 1984 Dec 8;233:712-713

HSL3627
Collier J.
Unconvincing reassurance from the ABPI.
Lancet 1984 Dec 1;2(8414):1280

HSL3692
Re: the promotion of Binotal
1984 Dec 01

HSL9021
Schwartz H.
Are doctors' offices troubled waters for the industry?
Pharmaceutical Executive 1984 Dec;4:14, 16

HSL3625
Collier J.
Misleading advertisements: sanctions and corrections.
Lancet 1984 Nov 10;2(8411):1097-8

HSL3636
Statement on ethical conduct in research by the Infectious Diseases Society of America.
J Infect Dis. 1984 Nov 01;150(5):792-3

HSL9036
Pharmaceutical R&D must be encouraged and supported, CMA tells the Eastman Commission
Canadian Medical Association Journal 1984 Nov 1;131:1095-1097

HSL9037
Give us more protection, innovative drug manufacturers tell Eastman Commission
Canadian Medical Association Journal 1984 Nov 1;131:1097-1098

HSL3664
Yudkin JS.
Use and misuse of drugs in the Third World.
Dan Med Bull 1984 Nov;31

HSL9017
Schwartz H.
There's no profit in misunderstanding
Pharmaceutical Executive 1984 Nov;4:14, 16-17

HSL9018
Shuler J.
Indirect Rx advertising to consumers
Pharmaceutical Executive 1984 Nov;4:10

HSL9023
Schaaf D.
Hospital pharmacy and industry-rivals or partners
Krankenhauspharmazie 1984 Nov;5:347-351

HSL9039
Buchanan C.
Requiring rational promotions as part of a bid request
American Journal of Hospital Pharmacy 1984 Nov;41:2320, 2324

HSL3651
Rawlins MD.
Doctors and the drug makers.
Lancet 1984 Oct 6;2(8406):814

HSL3691
Gabe L.
You can reach the hard-to-see MD!
Medical Marketing & Media 1984 Oct;19:63, 66, 68-69

HSL9025
Merchandising alert: new items push sales out front
National Association of Retail Druggists Journal 1984 Oct;106:10-11

HSL9033
Thompson RC.
Flaw in cytotoxic testing: there's no proof it works
FDA Consumer 1984 Oct;18:34-36

HSL3639
Lexchin J.
Pharmaceutical advertising in medical journals.
Can Med Assoc J 1984 Sep 15;131(6):544-6

HSL3618
Some dodgy claims for pirbuterol (Exirel)--a beta 2 agonist.
Drug Ther Bull. 1984 Sep 10;22(18):70-2

HSL9028
Rockwell T.
Rx ads to consumers at the threshold
Pharmaceutical Executive 1984 Sep;4:52, 54, 58

HSL9029
Prescription drug prices soar after years of moderate increases
American Pharmacy 1984 Sep:16-17

HSL9030
Abbott B.
Getting your OTC campaign in shape
Pharmaceutical Executive 1984 Sep;4:60, 62, 67

HSL9031
Fisher JJ.
Cautiously circling the issue of Rx consumer ads
Pharmaceutical Executive 1984 Sep;4:46, 50-51, 102

HSL9042
Jenne JW.
Unintentional overdose of theophylline: challenge to the pharmaceutical industry.
Clin Pharm 1984 Sep-Oct;3(5):523-4

HSL3690
Joubert PH, Skene D.
Attitudes of private medical practitioners towards package inserts and other drug information sources.
S Afr Med J 1984 Aug 25;66(8):306-7

HSL3685
Altman L.
Dealing with conflicts of interest [4th of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):405

HSL3686
Cohen SM.
Dealing with conflicts of interest [1st of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404

HSL3687
Goldstone RA.
Dealing with conflicts of interest [2nd of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404

HSL3688
Nightingale SD, Ansell D, Cohen M, Danel I, Hoffman A, Kiken S, Orris P, Patch O, Ringel P, Sable R, Schiff G, Schiff R, Sherer R, Shansky R, Trainor W, Tully J, Watson C, Kallal C.
Dealing with conflicts of interest [3rd of 4 letters]
New England Journal of Medicine 1984 Aug 9;311(6):404-405

HSL3689
Relman AS.
Dealing with conflicts of interest [Editor's reply]
New England Journal of Medicine 1984 Aug 9;311(6):405

HSL9034
Hildebrand N.
Physician and pharmacist: competing or essentially complementing?
Deutsche Apotheker Zeitung 1984 Aug 9;124:1573-1576

HSL9016
Final judgement on advertising-U.S. district court
American Pharmacy 1984 Aug:74-76

HSL3683
Collier JG, Pilkington TRE.
Human insulin: a misleading advertisement?
British Medical Journal 1984 Jul 21;289:191

HSL3684
Knight RK, Gennery BA.
Human insulin: a misleading advertisement? [reply]
British Medical Journal 1984 Jul 21;289:191

HSL3661
Wolffers I.
Telling doctors in a developing country about phenylbutazone.
Lancet 1984 Jul 7;2(8393):44

HSL3680
MLAM’s first six months
MLAM Newsletter 1984 Jul 01:1-2

HSL3681
Re: the promotion of ethylestrenol
1984 Jul 01

HSL3676
Mastroni N.
The industry is tuning out on direct-to-consumer advertising.
Med Mark Media 1984 Jul;19(7):10-1,

HSL3682
Gouveia WA.
Hospital pharmacy and industry--conflict and collaboration.
Am J Hosp Pharm 1984 Jul;41(7):1391-4

HSL13981
Adelson B.
When novices surpass experts: The difficulty of a task may increase with expertise.
Journal of Experimental Psychology: Learning, Memory, and Cognition 1984 Jul;10(3):483-495
http://content.apa.org/journals/xlm/10/3/483

HSL3619
Bansinath M, Sequeira RP, Shukla VK, Mathur VS.
Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint.
Int J Clin Pharmacol Ther Toxicol 1984 Jun;22(6):279-83

HSL9046
Rantucci M, Segal HJ.
Public awareness: assessment of the public response to a display illustrating community pharmacists' roles and services
Canadian Pharmaceutical Journal 1984 Jun;117:272-275

HSL9047
Gunston G.
Pharmaceutical marketing: but my market is different
Pharmaceutical Journal 1984 May 12;232:588-589

HSL3677
Re: the promotion of Lomotil
1984 May 01

HSL3678
Donald AG.
Doctors and the pharmaceutical industry
Journal of the Royal College of General Practitioners 1984 May;34:301

HSL3679
Liebman M.
Prescription drug advertising to the general public.
Hosp Pract (Off Ed) 1984 May;19(5):13,

HSL14107
Gallus M.
Under The Sugar Coating
The Globe and Mail (Canada) 1984 Apr 21

HSL3631
Crompton GK, Grant IW.
Pirbuterol.
Lancet 1984 Apr 7;1(8380):795

HSL3673
Re: the promotion of dipyrone
1984 Apr 01

HSL3674
Physicians, pharmacists, and consumers react to a direct-to-consumer campaign
Medical Marketing & Media 1984 Apr 01;19(4):24, 26

HSL3657
Tse CS, Mansur JM.
Drug industry response time.
Drug Intell Clin Pharm 1984 Apr;18(4):325

HSL3675
Atkinson AJ Jr, Becker RE, Galletti PM, Jefferis JE, Wroblewski R.
University and pharmaceutical industry cooperation: the need to plan for the future.
Clin Pharmacol Ther 1984 Apr;35(4):431-7

HSL3624
Collier J.
The Medicines Act and the ABPI code.
Lancet 1984 Mar 24;1(8378):682-3

HSL9041
Maclay WP, Crowder D, Spiro S, Turner P.
Postmarketing surveillance: practical experience with ketotifen.
Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):911-4
Link to source with long URL

HSL3672
Urbanski A.
Drug marketers write an Rx for consumers
Sales & Marketing Management 1984 Mar 12;132:74-75, 78

HSL9050
Spink JD.
Parallel imports
Pharmaceutical Journal 1984 Mar 10;232:275-276

HSL3629
Cox P.
Rules of conduct and the pharmaceutical industry.
Lancet 1984 Mar 3;1(8375):517